These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 18507487)

  • 1. Antipsychotic polypharmacy, part 1: Shotgun approach or targeted cotreatment?
    Correll CU
    J Clin Psychiatry; 2008 Apr; 69(4):674-5. PubMed ID: 18507487
    [No Abstract]   [Full Text] [Related]  

  • 2. Antipsychotic Polypharmacy in Schizophrenia: Why Not?
    Guinart D; Correll CU
    J Clin Psychiatry; 2020 Apr; 81(3):. PubMed ID: 32369690
    [No Abstract]   [Full Text] [Related]  

  • 3. Antipsychotic polypharmacy: never say never, but never say always.
    Stahl SM
    Acta Psychiatr Scand; 2012 May; 125(5):349-51. PubMed ID: 22506490
    [No Abstract]   [Full Text] [Related]  

  • 4. Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret?
    Stahl SM
    J Clin Psychiatry; 1999 Jul; 60(7):425-6. PubMed ID: 10453794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interventions to reduce antipsychotic polypharmacy: a systematic review.
    Tani H; Uchida H; Suzuki T; Fujii Y; Mimura M
    Schizophr Res; 2013 Jan; 143(1):215-20. PubMed ID: 23158205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.
    Ganguly R; Kotzan JA; Miller LS; Kennedy K; Martin BC
    J Clin Psychiatry; 2004 Oct; 65(10):1377-88. PubMed ID: 15491242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotic polypharmacy: are two ever better than one?
    Goff DC; Dixon L
    Am J Psychiatry; 2011 Jul; 168(7):667-9. PubMed ID: 21724670
    [No Abstract]   [Full Text] [Related]  

  • 8. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial.
    Constantine RJ; Andel R; McPherson M; Tandon R
    Schizophr Res; 2015 Aug; 166(1-3):194-200. PubMed ID: 26141142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: A nation-wide pharmacoepidemiological study.
    Sneider B; Pristed SG; Correll CU; Nielsen J
    Eur Neuropsychopharmacol; 2015 Oct; 25(10):1669-76. PubMed ID: 26256007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
    Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
    Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia.
    Suzuki T; Uchida H; Watanabe K; Yagi G; Kashima H
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):361-9. PubMed ID: 14751434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and social determinants of antipsychotic polypharmacy for Chinese patients with schizophrenia.
    Xiang YT; Weng YZ; Leung CM; Tang WK; Ungvari GS
    Pharmacopsychiatry; 2007 Mar; 40(2):47-52. PubMed ID: 17447172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monotherapy versus polypharmacy for hospitalized psychiatric patients.
    Strous RD; Lerner V
    Am J Psychiatry; 2005 Mar; 162(3):631-2; author reply 632-3. PubMed ID: 15741496
    [No Abstract]   [Full Text] [Related]  

  • 14. The evolution of antipsychotic switch and polypharmacy in natural practice--a longitudinal perspective.
    Tsutsumi C; Uchida H; Suzuki T; Watanabe K; Takeuchi H; Nakajima S; Kimura Y; Tsutsumi Y; Ishii K; Imasaka Y; Kapur S
    Schizophr Res; 2011 Aug; 130(1-3):40-6. PubMed ID: 21624824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004.
    Gilmer TP; Dolder CR; Folsom DP; Mastin W; Jeste DV
    Psychiatr Serv; 2007 Jul; 58(7):1007-10. PubMed ID: 17602020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotic polypharmacy, Part 2: Why use 2 antipsychotics when 1 is not good enough?
    Correll CU
    J Clin Psychiatry; 2008 May; 69(5):860-1. PubMed ID: 18681762
    [No Abstract]   [Full Text] [Related]  

  • 17. Measuring efficacy of polypharmacy in schizophrenic inpatients.
    Lindenmayer JP
    J Clin Psychiatry; 2004 Aug; 65(8):1148; author reply 1148. PubMed ID: 15323607
    [No Abstract]   [Full Text] [Related]  

  • 18. [Polypharmacy in the treatment of schizophrenia].
    Messer T; Tiltscher C; Schmauss M
    Fortschr Neurol Psychiatr; 2006 Jul; 74(7):377-91. PubMed ID: 16804806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in Hungary.
    Katona L; Czobor P; Bitter I
    Schizophr Res; 2014 Jan; 152(1):246-54. PubMed ID: 24275583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prescribing of Clozapine and Antipsychotic Polypharmacy for Schizophrenia in a Large Medicaid Program.
    Tang Y; Horvitz-Lennon M; Gellad WF; Lave JR; Chang CH; Normand SL; Donohue JM
    Psychiatr Serv; 2017 Jun; 68(6):579-586. PubMed ID: 28196460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.